✦ LIBER ✦

Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)

✍ Scribed by Hye J KANG; Seung S LEE; Kyeong M KIM; Tae H CHOI; Gi J CHEON; Won S KIM; Cheolwon SUH; Sung H YANG; Sang M LIM

Book ID: 111318889
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 567 KB
Volume: 7
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2011.01393.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy for patients with rel

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma

✍ Thomas E. Witzig 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 86 KB

Radioimmunotherapy using131I-rituximab i

Radioimmunotherapy using131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience

✍ Maren Bienert; Ingrid Reisinger; Stefanie Srock; Beatrice I Humplik; Christel Re 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 249 KB

Zevalin radioimmunotherapy offers safe a

Zevalin radioimmunotherapy offers safe and effective therapy for relapsed or refractory, B cell non-Hodgkin's lymphoma (nhl)

✍ M. Saleh; C.A. White; T.E. Witzig; L. Gordon; G.A. Wiseman; C. Emmanouilides; J. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 360 KB

Rituximab in three children with relapse

Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma

✍ Maaike J. De Vries; Anjo J. P. Veerman; Christian M. Zwaan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Inducible lymphokine-activated killer (L

Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)

✍ Kenneth W. Zamkoff; Nora P. Watman; David B. Duggan; Bernard J. Poiesz; Arlan J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell